Vir, prostate cancer

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate ...
Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...
Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Vir Biotechnology, Inc. (Nasdaq: VIR) is experiencing a massive surge in the stock market, climbing an impressive +74.08% or $5.85 to $13.74 in Wednesday’s trading session at 12:22 PM EST. This sharp ...
BofA raised the firm’s price target on TG Therapeutics (TGTX) to $10 from $9 and keeps an Underperform rating on the shares. While political and rate uncertainty continues to be an overhang, the firm ...